Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $107.
September 09, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Charles Duncan has reiterated an Overweight rating for Axsome Therapeutics, maintaining a price target of $107. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $107 by a reputable analyst suggests a positive outlook for Axsome Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100